Biophytis (BPTSY) AI Stock Analysis

• Market Cap: $4.13M
• Dividend Yield: N/A
• Average Volume (3M): 0.00
• Price to Earnings (P/E): ―
• Beta (1Y): 0.25
• Revenue Growth: N/A
• EPS Growth: 84.55%
• Country: US
• Employees: 22
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.96
• Shares Outstanding: 3,501,216
• 10 Day Avg. Volume: 0
• 30 Day Avg. Volume: 0
• PEG Ratio: 0.02
• Price to Book (P/B): -1.60
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.79
• Enterprise Value/Market Cap: 2.57
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -1.29
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -3.86
• Revenue Forecast (FY): $1.76M

• Rating: 35 Underperform
• Price Target: ―

Biophytis faces significant financial challenges, with ongoing losses and negative equity posing major risks. While there is some short-term technical strength, the long-term technical indicators and valuation metrics highlight weaknesses. The lack of substantial earnings call information increases uncertainty, contributing to a low overall score.

Biophytis Business Overview & Revenue Model

Company Description

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics targets and activates key biological resilience pathways that can protect against and counteract the effects of the multiple biological and environmental stresses, including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is BIO101, an orally administered small molecule in development to treat neuromuscular diseases, including sarcopenia, Duchenne muscular dystrophy (DMD), and obesity, as well as treatment of severe respiratory failure in patients suffering from COVID-19. It also develops BIO201, an orally administered small molecule for the treatment of retinopathies, including dry age-related macular degeneration, and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.

How the Company Makes Money

Biophytis generates revenue through the development and potential commercialization of its drug candidates. The company's revenue model primarily focuses on licensing agreements, partnerships, and collaborations with other pharmaceutical companies, which may involve upfront payments, milestone payments, and royalties based on product sales. Additionally, Biophytis may receive funding from grants and research collaborations to support its clinical trials and research initiatives. The success of its revenue model is contingent upon the progression and approval of its drug candidates through clinical trials and regulatory processes.

Biophytis Financial Statement Overview

Summary

Biophytis is experiencing significant financial distress characterized by continuous operating losses, negative equity, and reliance on external financing. The absence of revenue poses a major challenge, while the ongoing cash burn and high debt levels present substantial risks to financial stability.

Income Statement

Biophytis has faced consistent financial challenges with no revenue generation over the past years. The company has significant negative EBIT and EBITDA margins due to high operating losses. Net profit margins remain deeply negative, reflecting the ongoing unprofitability.

Balance Sheet

The balance sheet reveals significant financial instability with negative stockholders' equity, indicating a concerning level of leverage. The debt-to-equity ratio cannot be calculated due to negative equity, and the company relies heavily on debt financing. Total liabilities exceed total assets, further highlighting financial vulnerability.

Cash Flow

Cash flow analysis shows negative operating and free cash flows, indicating poor cash generation capabilities. However, a reduction in negative free cash flow over time suggests some improvements in cash management. The company is heavily reliant on financing activities for cash inflow.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	-803.00K	-484.00K	-311.00K	-280.00K
EBITDA	-8.26M	-13.80M	-22.79M	-26.50M	-13.66M
Net Income	-10.38M	-17.03M	-24.22M	-31.16M	-25.52M
Balance Sheet
Total Assets	6.90M	11.96M	21.99M	36.26M	27.21M
Cash, Cash Equivalents and Short-Term Investments	78.00K	5.93M	11.05M	25.16M	18.77M
Total Debt	9.84M	8.27M	12.13M	17.55M	9.10M
Total Liabilities	16.60M	15.85M	23.90M	30.56M	20.38M
Stockholders Equity	-9.67M	-3.86M	-1.88M	5.83M	2.30M
Cash Flow
Free Cash Flow	-8.64M	-13.09M	-19.13M	-24.14M	-10.08M
Operating Cash Flow	-8.64M	-12.87M	-18.99M	-23.80M	-9.86M
Investing Cash Flow	10.00K	370.00K	-17.00K	12.16M	-12.71M
Financing Cash Flow	3.14M	7.03M	6.13M	29.71M	21.95M

Biophytis Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.60
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BPTSY, the sentiment is Negative. The current price of 1.6 is above the 20-day moving average (MA) of 1.44, below the 50-day MA of 1.72, and below the 200-day MA of 2.10, indicating a bearish trend. The MACD of -0.15 indicates Positive momentum. The RSI at 25.65 is Positive, neither overbought nor oversold. The STOCH value of 6.69 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BPTSY.

Biophytis Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
INM	40 Underperform	$4.49M	-0.17	-72.10%	―	-3.27%	51.83%
BPTSY	35 Underperform	$4.13M	―	―	―	―	84.55%
ONCO	33 Underperform	$4.76M	>-0.01	-254.09%	―	-9.34%	93.84%
OGEN	29 Underperform	$4.66M	-0.04	―	―	-100.00%	85.99%